Global Acetylcholinesterase Inhibitors Market - 2024-2031

Global Acetylcholinesterase Inhibitors Market - 2024-2031

The global acetylcholinesterase inhibitors market reached US$ 5.03 billion in 2023 and is expected to reach US$ 9.03 billion by 2031, growing at a CAGR of 7.8% during the forecast period 2024-2031.

Acetylcholinesterase inhibitors (AChEIs) are a specific kind of drug that is essential in the treatment of a variety of neurological illnesses, including Alzheimer's disease and other forms of dementia. These medications work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine, a critical neurotransmitter involved in memory, learning, and muscular activity. AChEIs block acetylcholine breakdown, increasing its levels and prolonging its effect at synaptic junctions, hence improving cholinergic communication in the brain.

The increasing prevalence of alzheimer's disease is the driving factor that drives the market over the forecast period. For instance, according to Alzheimer's Disease International, Every three seconds, someone somewhere in the globe develops dementia. In 2020, more than 55 million individuals globally will be living with dementia. This figure will nearly double every twenty years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will occur in underdeveloped countries. Already, 60% of people with dementia live in low- and middle-income nations, by 2050, the proportion will grow to 71%. China, India, and their South Asian and Western Pacific neighbors are experiencing the fastest aging population rise.

Market Dynamics: Drivers & Restraints

Increasing prevalence of neurodegenerative diseases

The rising burden and increasing prevalence of neurodegenerative diseases is expected to be a significant factor in the growth of the global acetylcholinesterase inhibitors market. The increased burden and prevalence of neurodegenerative disorders, including Alzheimer's disease and other types of dementia, are key drivers of the global acetylcholinesterase inhibitors market. As the population ages and the prevalence of these debilitating disorders increases, there will be a greater demand for effective therapeutic choices.

For instance, according to the World Health Organization, Dementia affects around 55 million individuals globally, with more than 60% living in low- and middle-income countries. Every year, there are roughly 10 million new cases. Dementia is caused by a range of brain-related disorders and accidents. Alzheimer's disease is the most common type of dementia and may account for 60-70% of cases. Dementia is now the seventh largest cause of death and one of the primary causes of impairment and dependency among the elderly worldwide. Women are disproportionately impacted by dementia, both directly and indirectly. Women had greater disability-adjusted life years and mortality rates from dementia, but they also gave 70% of care hours for people with dementia.

The increased burden and prevalence of neurodegenerative disorders are major factors supporting the growth of the acetylcholinesterase inhibitors market. As more people are diagnosed with diseases such as Alzheimer's disease, the demand for effective treatments will increase, leading to innovation and growth in this vital section of the pharmaceutical business. The continuous commitment to research and development will be critical in addressing both present obstacles and future prospects for effective neurodegenerative disease management.

Side Effects and Tolerability Issues Associated with Drugs

Factors such as side effects and tolerability issues associated with drugs are expected to hamper the global acetylcholinesterase inhibitors market. For instance, according to the National Institute of Health, acetylcholinesterase inhibitors increase the overall amount of acetylcholine available. Thus, symptoms of overstimulation of the parasympathetic nervous system, such as increased hypermotility, hypersecretion, bradycardia, miosis, diarrhea, and hypotension, may be present. One of the primary concerns with AChEIs is the incidence of gastrointestinal adverse effects. Common symptoms include nausea, vomiting, diarrhea, and anorexia.

Segment Analysis

The global acetylcholinesterase inhibitors market is segmented based on application, drug type, distribution channel, and region.

Alzheimer’s disease segment is expected to dominate the global acetylcholinesterase inhibitors market share

Alzheimer’s disease segment is expected to dominate the global acetylcholinesterase inhibitors market share. The Alzheimer's disease market is anticipated to dominate the global acetylcholinesterase inhibitors market, owing to the disease's increasing prevalence and the growing acceptance of acetylcholinesterase inhibitors (AChEIs) as a conventional treatment. Alzheimer's disease, the most common type of dementia, affects millions of people globally, and its rising prevalence is a major factor driving the growth of this market sector. For instance, according to the Alzheimer’s Association, Alzheimer's dementia affects around 6.7 million Americans aged 65 and older. If no medical breakthroughs are developed to prevent, halt, or cure Alzheimer's disease, this figure might rise to 13.8 million by 2060. In 2019, official death certificates documented 121,499 deaths from Alzheimer's disease, making it the sixth-highest cause of death in the United States.

The acetylcholinesterase inhibitors play an important role in the treatment of alzheimer’s disease. Acetylcholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are among the few approved pharmaceutical treatments for Alzheimer's disease symptoms. These drugs act by preventing the breakdown of acetylcholine, a neurotransmitter necessary for memory and cognitive function. AChEIs, which increase acetylcholine levels in the brain, can assist improve cognitive performance and halt symptom development in people with mild to moderate Alzheimer's disease. Numerous clinical trials have supported the efficacy of these medications, confirming their status as an essential component in Alzheimer's treatment.

Geographical Analysis

North America is expected to hold a significant position in the global acetylcholinesterase inhibitors market share

North America is expected to hold a significant portion of the global acetylcholinesterase inhibitors market. North America is expected to dominate the global acetylcholinesterase inhibitors market, owing to demographic trends, high prevalence rates of neurological disorders, and developments in healthcare infrastructure. As the region experiences an increase in the number of people diagnosed with Alzheimer's disease and other forms of dementia, there will be a greater demand for effective treatment alternatives like acetylcholinesterase inhibitors.

For instance, according to the Alzheimer’s Association, Alzheimer's affects around 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Alzheimer's disease was the fifth greatest cause of mortality for those aged 65 and up. Health and long-term care costs for people with dementia are expected to exceed $360 billion in 2024 and nearly $1 trillion by 2050. At the age of 45, women have a one-in-five lifetime risk of developing Alzheimer's, while males have one in ten. Over 11 million Americans offer unpaid care to persons suffering from Alzheimer's disease or other forms of dementia.

North America has an established healthcare system, making improved therapeutic choices available to patients suffering from neurodegenerative illnesses. The region is home to various research institutions and pharmaceutical businesses that develop and market AChEIs, ensuring that patients have access to the most recent therapy options. The availability of well-established hospital systems, outpatient facilities, and specialized dementia care centers improves patient access to critical drugs and supportive services.

Asia Pacific is growing at the fastest pace in the global acetylcholinesterase inhibitors market

The Asia Pacific area is emerging as the fastest-growing market for acetylcholinesterase inhibitors (AChEIs), owing to a combination of demographic, healthcare, and economic drivers. As the frequency of neurodegenerative disorders, particularly Alzheimer's disease and other kinds of dementia, rises in this highly populated region, there will be a huge increase in demand for effective therapy choices. For instance, according to the Alzheimer’s Association, The estimated dementia prevalence in individuals aged 60 and up in India is 7.4%. There are an estimated 8.8 million Indians over the age of 60 who suffer from dementia. Dementia affects more women than men, and it is more prevalent in rural regions than in cities.

Competitive Landscape

The major global players in the global acetylcholinesterase inhibitors market include Eisai Co., Ltd., Pfizer Inc., Alkem, Zydus Group, Teva Pharmaceutical Industries Ltd, Indena S.p.A., Alpha Cognition, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Merz Pharma among others.

Emerging Players

Biogen, Anavex Life Sciences Corp. among others

Key Developments
• In July 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. ALPHA-1062 is absorbed in the small intestine as an insert medication. The addition of a benzyl ester to galantamine inhibits its binding to AChE in the gastrointestinal nervous system. This minimizes overstimulation of local neurons, and gastrointestinal adverse events, and enhances absorption.

Why Purchase the Report?
• To visualize the global acetylcholinesterase inhibitors market segmentation based on application, drug type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global acetylcholinesterase inhibitors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global acetylcholinesterase inhibitors market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.